Astellas and Seattle Genetics Report Results of Enfortumab Vedotin in P-II EV-201 Study for Patients with Locally Advanced or Metastatic Urothelial Cancer #ASCO2019

Astellas and Seattle Genetics Report Results of Enfortumab Vedotin in P-II EV-201 Study for Patients with Locally Advanced or Metastatic Urothelial Cancer #ASCO2019

Shots:

  • The P-II EV-201 study involves assessing of Enfortumab Vedotin in patients with locally advanced or metastatic urothelial cancer who have been previously treated with a PD-1/L1 inhibitor including those who have also been treated with Pt-CT
  • P-II EV-201 results: ORR 44%; DOR 7.6 mos.; mOS 11.7 mos.; mPFS 5.8 mos.; CR 12%; presented at ASCO 2019
  • Enfortumab vedotin is an investigational ADC candidate targeting Nectin-4 protein, currently evaluated in P-III EV-301 study for LA or metastatic urothelial cancer. In 2007, Seattle and Astellas entered a co-development deal for enfortumab vedotin, plans to submit BLA to FDA based on EV-201 results

Click here to read full press release/ article | Ref: Astellas| Image: Behance